GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptose Biosciences Inc (OTCPK:APTOF) » Definitions » EBIT per Share

APTOF (Aptose Biosciences) EBIT per Share : $-47.27 (TTM As of Dec. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Aptose Biosciences EBIT per Share?

Aptose Biosciences's EBIT per Share for the three months ended in Dec. 2024 was $-0.58. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-47.27.

During the past 3 years, the average EBIT per Share Growth Rate was 49.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was 24.90% per year. During the past 10 years, the average EBIT per Share Growth Rate was 15.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Aptose Biosciences's EBIT per Share or its related term are showing as below:

APTOF' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -20.7   Med: 21.35   Max: 49.8
Current: 49.8

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Aptose Biosciences was 49.80% per year. The lowest was -20.70% per year. And the median was 21.35% per year.

APTOF's 3-Year EBIT Growth Rate is ranked better than
90.69% of 1235 companies
in the Biotechnology industry
Industry Median: 7.9 vs APTOF: 49.80

Aptose Biosciences's EBIT for the three months ended in Dec. 2024 was $-1.15 Mil.


Aptose Biosciences EBIT per Share Historical Data

The historical data trend for Aptose Biosciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptose Biosciences EBIT per Share Chart

Aptose Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -306.42 -330.54 -207.82 -227.59 -36.08

Aptose Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.90 -22.28 -13.16 -11.25 -0.58

Aptose Biosciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Aptose Biosciences's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

EBIT per Share(A: Dec. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-25.223/0.699
=-36.08

Aptose Biosciences's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

EBIT per Share(Q: Dec. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-1.153/2.006
=-0.57

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptose Biosciences  (OTCPK:APTOF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.


Aptose Biosciences EBIT per Share Related Terms

Thank you for viewing the detailed overview of Aptose Biosciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptose Biosciences Business Description

Traded in Other Exchanges
Address
66 Wellington Street West, Suite 5300, TD Bank Tower Box 48, Toronto, ON, CAN, M5K 1E6
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Executives
William G. Rice director, officer: Chair, President & CEO C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Bernd R. Seizinger director 535 BOYLSTON STREET, BOSTON MA 02116
Fletcher Payne officer: SR VP & Chief Fin. Officer 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Philippe Ledru officer: Chief Commercial Officer C/O APTOSE BIOSCIENCES INC., 2511 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Denis R Burger director CYTODYN INC., 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Erich Platzer director
Rafael Bejar officer: Chief Medical Officer C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Wilson Donald R. Jr. 10 percent owner 540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Drw Holdings, Llc 10 percent owner 540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Drw Commodities, Llc 10 percent owner 540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Warren Whitehead director C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Gregory K. Chow officer: Senior VP & CFO C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Jotin Marango officer: Senior VP, Chief Bus. Officer C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Mark D. Vincent director C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3